Literature DB >> 9326728

Sulfonamides do not reach the retina in therapeutic amounts after topical application to the cornea.

C W Conroy1.   

Abstract

Retinal drug concentrations were measured in treated and fellow eyes following topical administration of two potent and permeable carbonic anhydrase inhibitors, MK-927 and trifluoromethanesulfonamide (CF3SO2NH2) in the rabbit. Administration of 2 or 5 drops 2% MK-927 or 2% CF3SO2NH2 gave at 1 hr 1.5-9 microM drug in the retinas of treated eyes and 1.3-3.7 microM drug in the retinas of the fellow eye. After allowance was made for the blood content of the retinas (1.4-13%) and drug contained in whole blood due to systemic absorption, little (< 1.4 microM) or no net accumulation in retina could be documented. In a second series of experiments animals were treated with 5 mg/kg i.v. of either MK-927 or CF3SO2NH2 in order to fully saturate red cell carbonic anhydrase prior to topical administration of drug. For MK-927 there was a net accumulation in retina 3 hrs following topical administration in both treated and fellow eyes (3-4 microM) which was approximately 1/4 the concentration in plasma, suggesting that some drug had permeated the blood-retinal barrier. Similar results were obtained with CF3SO2NH2, giving no difference between treated and fellow eyes; retinal concentrations were approximately 90% of plasma concentrations. These results suggest that there is no direct access to retina by posterior or uveoscleral drainage of topically applied sulfonamides other than systemically absorbed drug.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9326728     DOI: 10.1089/jop.1997.13.465

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  2 in total

1.  The clinical efficacy of a topical dorzolamide in the management of cystoid macular edema in patients with retinitis pigmentosa.

Authors:  Yasuhiro Ikeda; Toshio Hisatomi; Noriko Yoshida; Shoji Notomi; Yusuke Murakami; Hiroshi Enaida; Tatsuro Ishibashi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-01-04       Impact factor: 3.117

Review 2.  Clinical pharmacokinetics of dorzolamide.

Authors:  Jens Martens-Lobenhoffer; Peter Banditt
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.